Cathie Wood and Ark Invest currently hold $392.5 million worth of Crispr Therapeutics (CRSP) stock in their main ETF fund, ARKK. Crispr is currently the second-largest holding in the ARKK fund.
Risk and Disclaimer:The content shared by the author represents only their personal views and does not reflect the position of CoinWorldNet (币界网). CoinWorldNet does not guarantee the truthfulness, accuracy, or originality of the content. This article does not constitute an offer, solicitation, invitation, recommendation, or advice to buy or sell any investment products or make any investment decisions
No Comments
edit
comment
collection
like
share